米吉珠单抗诱导治疗溃疡性结肠炎的真实世界有效性与安全性:一项多中心回顾性观察研究
该多中心回顾性队列研究纳入52例首次接受米吉珠单抗治疗的溃疡性结肠炎患者,评估第0至12周的部分Mayo评分变化。部分Mayo评分中位数从5降至2(p<0.001),第12周临床缓解率为44.2%,未发生导致永久停药的 adverse events 或死亡。
要点
- 部分Mayo评分中位数从第0周5降至第12周2(p<0.001)。
- 第12周临床缓解率44.2%,CRP缓解率67.3%,LRG缓解率27.3%。
- 未发生导致永久停用米吉珠单抗的不良事件或死亡。
核心结论
- 该真实世界研究显示米吉珠单抗在溃疡性结肠炎患者中具有短期有效性和安全性。
研究设计与样本
- 多中心回顾性队列研究,纳入三家机构中2023年6月至2024年4月首次接受米吉珠单抗治疗的溃疡性结肠炎患者,共52例。
主要发现
- 部分Mayo评分中位数(四分位距)从第0周5(3-6)降至第12周2(0-3),p<0.001。
- CRP水平从第0周3.8(0.9-7.3)mg/L降至第12周1.8(0.5-4.0)mg/L,p=0.015。
- LRG水平从第0周20.1(16.3-23.2)μg/mL降至第12周15.9(12.8-23.2)μg/mL,p=0.014。
- 第12周临床缓解率(部分Mayo评分<2且直肠出血亚评分为0)为44.2%,CRP缓解率(<3.0 mg/L)为67.3%,LRG缓解率(<12.7 μg/mL)为27.3%。
- 诱导治疗期间未发生导致永久停用米吉珠单抗的不良事件或死亡。
关键数值与推荐
- 临床缓解定义为部分Mayo评分<2且直肠出血亚评分为0,第12周缓解率为44.2%。
- CRP缓解定义为<3.0 mg/L,第12周缓解率为67.3%。
- LRG缓解定义为<12.7 μg/mL,第12周缓解率为27.3%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In randomised controlled trials, mirikizumab achieved clinical remission and improved outcomes of patients with moderate to severe ulcerative colitis (UC). However, there is currently no real-world evidence for mirikizumab. AIM: To evaluate the real-world effectiveness and safety of mirikizumab. METHODS: In a retrospective cohort study among three facilities, we included patients with UC who first received mirikizumab between June 2023 and April 2024. The primary outcome was the change in the partial Mayo score (PMS) from week 0 to 12. Secondary outcomes included changes in serum C-reactive protein (CRP) and leucine-rich α2-glycoprotein (LRG) levels from week 0 to 12; clinical remission rate (PMS < 2 with rectal bleeding subscore of 0), CRP remission rate (< 3.0 mg/L), and LRG remission rate (< 12.7 μg/mL) at week 12; and adverse events during induction therapy. RESULTS: We included 52 patients. Median (interquartile range) PMS decreased from week 0 to 12 (5 [3-6] to 2 [0-3], p < 0.001). CRP and LRG levels also decreased (CRP: 3.8 [0.9-7.3] to 1.8 [0.5-4.0] mg/L, p = 0.015; LRG: 20.1 [16.3-23.2] to 15.9 [12.8-23.2] μg/mL, p = 0.014). Rates of clinical remission, CRP remission, and LRG remission at week 12 were 44.2%, 67.3%, and 27.3%, respectively. There were no adverse events leading to permanent discontinuation of mirikizumab or death. CONCLUSION: This real-world study demonstrated the short-term effectiveness and safety of mirikizumab in patients with UC.
引用
- Takagi Y, Sato T, Nishiguchi T, et al. Real-World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study. Aliment Pharmacol Ther. 2025. PMID: 40205711. doi:10.1111/apt.70140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。